---
title: "The Productivity Bureau has appointed Zhengmei Pharmaceuticals as the technical advisor for the \"New Industrial Acceleration Program\" project"
description: "The Hong Kong Productivity Council has been appointed by Jacobson Pharma's wholly-owned subsidiary, Zhengmei Pharmaceuticals, as the technical consultant for the \"New Industrial Acceleration Program,\""
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256679118.md"
published_at: "2025-09-10T06:47:30.000Z"
---

# The Productivity Bureau has appointed Zhengmei Pharmaceuticals as the technical advisor for the "New Industrial Acceleration Program" project

> The Hong Kong Productivity Council has been appointed by Jacobson Pharma's wholly-owned subsidiary, Zhengmei Pharmaceuticals, as the technical consultant for the "New Industrial Acceleration Program," providing smart manufacturing technology assessments and recommendations. The collaboration will customize assessments of factory and production line layouts to enhance production efficiency and quality control. The project budget is approximately HKD 600 million, with an expected funding amount of around HKD 200 million, and the production line is scheduled for trial production by the end of 2028. This project sets a demonstration case for the intelligent development of Hong Kong's life and health technology industry

The Hong Kong Productivity Council has officially appointed Jacobson Pharma (02633.HK) subsidiary, Zhengmei Pharmaceuticals, as the technical consultant for its "New Industrial Acceleration Program," providing comprehensive smart manufacturing technology assessments and recommendations for Zhengmei Pharmaceuticals' new factory development.

In this collaboration, the Productivity Council will offer customized assessment recommendations for factory and production line layout, intelligent system design, and specification requirements, as well as assist in system delivery, debugging, and validation. Leveraging its expertise in artificial intelligence and robotics technology, the Productivity Council will work with Zhengmei Pharmaceuticals to tailor seven intelligent production lines for oral solid dosage packaging, enhancing the company's production efficiency and quality control through advanced AI and robotics technology. The Productivity Council will also provide advice on the development of mobile robotic solutions to assist Zhengmei Pharmaceuticals in achieving automation in warehousing and material distribution, supporting its transformation and upgrading.

This project is set to commence within this year, with the production line expected to begin trial production and operation by the end of 2028. The total budget for this project is approximately HKD 600 million, with an expected funding amount of around HKD 200 million from the "Acceleration Program."

The Chairman of the Hong Kong Productivity Council, Chan Chu-hang, stated that as a market-oriented international new R&D institution, the Productivity Council has been actively cooperating with the Hong Kong SAR government to develop strategic life and health technology industries through the "Acceleration Program," establishing smart production lines in Hong Kong to drive the collaborative development of the upstream and downstream industrial chain with products of "Hong Kong R&D" and "Hong Kong Manufacturing," promoting the new industrialization of Hong Kong.

The Chairman and CEO of Jacobson Pharma, Chan Kwong-yeung, indicated that the Zhengmei Pharmaceuticals factory in Tai Po Innovation Park has become the first project supported by the "New Industrial Review Committee" under the "Acceleration Program," marking an important step in the company's corporate development and a key milestone in Hong Kong's medical innovation field. He believes this project will set a demonstration case for the intelligent development of Hong Kong's life and health technology industry, further consolidating Hong Kong's competitiveness in the innovation and technology sector

### Related Stocks

- [02633.HK - JACOBSON PHARMA](https://longbridge.com/en/quote/02633.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 机构 “最超配” 闪迪，“最低配” 英伟达 | 据摩根士丹利最新的统计：“机构对美国大型科技股的低配程度是 17 年来最大的” 相比 2025 年 Q4 的标普 500 指数权重，“$NVDA 仍然是机构低配程度最大的大型科技股，其次是苹果、微软、亚马逊和博通，而存储巨头闪迪则是 “最超 | [Link](https://longbridge.com/en/news/276289765.md) |
| 如果 OpenAI 估值 8300 亿美元，那谷歌该值多少？ | OpenAI 最新融资估值约 8300 亿美元，约为 2027 年预期收入的 14 倍；而谷歌却仅约 6.7 倍。按倍数类比，谷歌与 OpenAI 之间存在约 2 倍的 “定价尺度差”。分析指出，市场过度放大了 AI 颠覆的风险，却忽视了谷 | [Link](https://longbridge.com/en/news/276509743.md) |
| 期权热点｜上周五 UVIX 涨 3%，部分看涨期权飙升 150% | 美东时间 02 月 13 日，2 倍做多恐慌指数期货 ETF 期权总成交 86443 张，看涨期权占比 82%，看跌期权占比 17%。 | [Link](https://longbridge.com/en/news/276030214.md) |
| 谷歌高层回应 AI 泡沫质疑：这是工业革命，但速度快 10 倍、规模大 10 倍 | 谷歌 CEO 在印度 AI 峰会上透露谷歌云积压订单已翻倍至 2400 亿美元，以此证明高额资本开支的合理性。DeepMind CEO 预测实现通用人工智能至少仍需 5-10 年。谷歌高层一致认为，AI 将从根本上改变中小企业和科学研究的工 | [Link](https://longbridge.com/en/news/276440500.md) |
| Select 医药控股｜10-K：2025 财年营收 54.53 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276384073.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.